An observational study in HIV - Human Immunodeficiency Virus, sponsored by Southwest Medical University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-09.
Sponsored by Southwest Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Acquired Immunodeficiency Syndrome with a site in China — 21 open to participants now, 24 under way, 1 of them phase 3. Acquired Immunodeficiency Syndrome · China.
Among the 87 studies in Acquired Immunodeficiency Syndrome with a site in China, this one is the 18th largest by planned enrollment of the 18 observational ones that give a count, is one of 7 that started in 2026, is one of 19 observational ones, reaches primary completion later than 14 of the 23 other live ones, and was the 79th registered.
3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →21 of the 87 studies in Acquired Immunodeficiency Syndrome with a site in China are open now. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 40+
Cell Energy Life Sciences Group Co. LTD · Sites in China
Ages 18–65
Guangzhou 8th People's Hospital · Sites in China
Ages 18–65
Guangzhou 8th People's Hospital · Sites in China
Ages 18–65
Guangzhou 8th People's Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 15 · Phase 3 8 · Phase 4 4
First in 2005; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 289 across 504 observational studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 108 across the 68 interventional studies, 400 across the 18 observational. Of the 33 that completed or were terminated, 7 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 87 have an industry lead sponsor. The 10 most frequent:
Southwest Medical University is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Southwest Medical University has 1 study filed under Acquired Immunodeficiency Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Acquired Immunodeficiency Syndrome with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07519538Southwest Medical UniversitySouthern Sichuan HIV Cohort Study Protocol | 2027-04-30 |
| NCT07577986First Affiliated Hospital of Zhejiang UniversityA Safety and Efficacy Trial of Chidamide Combined With NKG2D CAR-NK Cell Therapy for Reducing the HIV Viral Reservoir | 2027-05-01 |
| NCT07711210Jiangsu Aidea Pharmaceutical Group Co., Ltd.Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations | 2027-06-30 |
| NCT05939167Cell Energy Life Sciences Group Co. LTDMesenchymal Stem Cells Treatment for AIDS Patients at Late Stage | 2027-07-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 87 studies in Acquired Immunodeficiency Syndrome with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Multi-source data-integrated HIV cohort in four cities of southern Sichuan, China: a mixed retrospective-prospective study protocol.
This study is a mixed retrospective-prospective cohort study conducted across four prefecture-level cities in southern Sichuan Province, China: Luzhou, Zigong, Neijiang, and Yibin. These four cities together comprise 23 districts and counties, with HIV care delivered through a network of designated treatment institutions coordinated by local Centers for Disease Control and Prevention (CDC). The region exhibits substantial intra-regional variation in healthcare resources and HIV burden, with molecular epidemiological data showing predominant CRF01_AE (36.9%) and CRF07_BC (41.0%) subtypes and evidence of concentrated transmission clusters among older adults (aged ≥60 years).
Retrospective component Data are extracted from existing electronic medical records (EMRs), CDC surveillance registries, and pharmacy/insurance claims systems for the period from 1 January 2019 to 31 December 2025. This phase reconstructs individual-level historical trajectories of antiretroviral therapy (ART) engagement, laboratory monitoring (CD4, viral load), and clinical outcomes to establish the baseline cohort.
Prospective component From 1 January 2026 to 31 December 2026, newly diagnosed individuals and those transferring into care are enrolled consecutively with quota controls by city and age group (\<50, 50-64, ≥65 years). At scheduled clinic visits, trained interviewers administer tablet-based structured questionnaires capturing patient-reported outcomes, including health-related quality of life (MOS-HIV, EQ-5D-5L), mental health (PHQ-9, GAD-7), HIV stigma (Berger Stigma Scale), self-management capacity, social determinants of health, and treatment preferences via a discrete choice experiment (5 attributes, 9 choice sets). Clinical data continue to be collected from routine sources.
Data integration A deterministic linkage procedure uses the unique ART treatment code as the primary key, with probabilistic linkage for records where the code is missing. A linkage failure threshold of 5% triggers manual verification. All data are harmonized (ICD-10 diagnoses, YPID medication codes, standardized laboratory units) and stored on encrypted servers with restricted access.
Sample size Target enrolment is 2,000 participants across the four cities, accounting for an anticipated 15% loss to follow-up. This ensures ≥1,700 participants with complete 12-month outcome data, providing ≥200 virological failure events (assuming a 12% failure rate) to satisfy the "10 events per variable" rule for multivariable analyses.
Primary analysis The primary outcome is 12-month virological suppression (HIV RNA \<50 copies/mL). Logistic regression with stepwise variable selection (Akaike Information Criterion) is used, reporting adjusted odds ratios and 95% confidence intervals. Secondary analyses include time-to-event analysis for virological failure (≥1,000 copies/mL on two consecutive measures) using Cox proportional hazards models, with verification of the proportional hazards assumption.
Dynamic trajectory modeling Hidden Markov Models (HMM) are applied to repeated viral load and CD4 measurements to characterize unobserved latent states (e.g., stable suppression, immunological fluctuation, failure) and transition probabilities over time. Self-management capacity and socioeconomic status are included as time-invariant covariates.
Machine learning prediction Models are developed to predict 12-month virological failure (VL ≥50 copies/mL). Feature selection uses LASSO regression on a training set (70% of data). Four algorithms are compared: logistic regression (benchmark), Random Forest, XGBoost, and a stacked ensemble. Hyperparameter tuning uses grid search with five-fold cross-validation on a validation set (10%). Performance is evaluated on a held-out test set (20%) using AUC-ROC, Brier score, and calibration curves. Synthetic minority oversampling (SMOTE) is applied to the training set to address class imbalance. Model interpretability is enhanced with SHAP values.
Missing data Multiple imputation by chained equations (MICE) is performed for variables with >10% missingness under the missing at random assumption, generating five imputed datasets combined using Rubin's rules. Complete-case analysis serves as a sensitivity comparison.
Sensitivity analyses Alternative viral suppression thresholds (\<200 copies/mL and \<1,000 copies/mL), different loss-to-follow-up handling (inverse probability of censoring weighting), and restriction to participants with at least two viral load measurements are conducted to assess robustness of findings.
Ethics and dissemination The study has received approval from the Institutional Review Board of Southwest Medical University (approval number SWMUIRBKS-202509-0017) and is conducted in accordance with the Declaration of Helsinki. Written informed consent is obtained from all prospective participants (or legally authorized representatives for those with cognitive impairment). The study is registered with the Chinese Clinical Trial Registry (ChiCTR) prior to enrolment of the first prospective participant. Results will be published in peer-reviewed journals and presented at scientific conferences. De-identified analytical datasets will be made available upon reasonable request, subject to approval from the data governance committee and relevant ethics approvals.
The study population consists of people living with HIV (PLWH) who receive care at designated HIV treatment institutions across four prefecture-level cities in southern Sichuan Province, China: Luzhou, Zigong, Neijiang, and Yibin. These four cities collectively comprise 23 districts and counties with considerable intra-regional variation in healthcare resources and HIV burden.
Participants are recruited from outpatient clinics and community follow-up encounters at the participating study sites. The study employs a consecutive enrolment strategy with quota controls applied by city and age group (\<50, 50-64, ≥65 years) to ensure adequate representation across clinically relevant strata. The ≥65 years age stratum is deliberately oversampled to enable robust subgroup analyses of older adults, who face unique challenges including polypharmacy and age-related comorbidities.
The retrospective component includes individuals with historical records from 1 January 2019 to 31 December 2025. The
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
People living with HIV (PLWH) enrolled from four prefecture-level cities in southern Sichuan, China (Luzhou, Zigong, Neijiang, and Yibin). Participants are recruited consecutively from outpatient clinics and community follow-up encounters, with quota controls applied by city and age group (\<50, 50-64, ≥65 years). All participants receive standard antiretroviral therapy (ART) per Chinese national guidelines. There is no assigned intervention. Data collection includes retrospective extraction of routine clinical, laboratory, and pharmacy records (2019-2025) and prospective collection of patient-reported outcomes (mental health, quality of life, stigma, self-management, treatment preferences) via structured questionnaires at baseline and follow-up visits. The primary outcome is 12-month virological suppression (HIV RNA \<50 copies/mL).
12-month virological suppression
Proportion of participants achieving HIV RNA \<50 copies/mL measured at the 12-month assessment window (±60 days). This binary outcome is derived from routinely collected viral load measurements extracted from CDC registries or hospital electronic medical records. If multiple measurements exist within the window, the value closest to the 12-month target date is used. This definition aligns with UNAIDS 95-95-95 targets and Chinese national treatment guidelines.
Time frame: 12 months (±60 days) after baseline
Virological failure
HIV RNA ≥1,000 copies/mL on two consecutive measurements after at least six months of antiretroviral therapy (ART), consistent with World Health Organization criteria. Analyzed as a time-to-event outcome, with event date corresponding to the first of the two confirmatory measurements.
Time frame: Up to 24 months (prospective follow-up period)
Change in CD4 count
Absolute change in CD4 cell count (cells/µL) from baseline to 12 months, calculated as CD4 at 12 months minus baseline CD4.
Time frame: Baseline and 12 months (±60 days)
Treatment persistence
Continuous antiretroviral therapy without interruption exceeding 30 days, derived from pharmacy dispensing records and CDC follow-up documentation. Interruptions identified based on gaps in medication refill records exceeding expected dispensing intervals.
Time frame: 12 months and 24 months
Health-related quality of life (MOS-HIV)
Physical health summary score and mental health summary score from the Medical Outcomes Study HIV Health Survey (MOS-HIV). Higher scores indicate better health-related quality of life.
Time frame: Baseline and 12 months (±60 days)
Depressive symptom severity (PHQ-9)
Total score on the Patient Health Questionnaire-9 (PHQ-9), range 0-27, with higher scores indicating more severe depressive symptoms. Established cut-point for probable depression is ≥10.
Time frame: Baseline and 12 months (±60 days)
Anxiety symptom severity (GAD-7)
Total score on the Generalized Anxiety Disorder-7 (GAD-7), range 0-21, with higher scores indicating more severe anxiety symptoms.
Time frame: Baseline and 12 months (±60 days)
HIV-related stigma (Berger Stigma Scale)
Total score on the Berger HIV Stigma Scale (BHSS) at baseline, measuring perceived HIV-related stigma.
Time frame: Baseline only
Plan to share: No — Individual participant data (IPD) will not be made publicly available. De-identified data may be shared only upon reasonable request and subject to approval by the study's Data Governance Committee and relevant institutional ethics review, as stated in the protocol. IPD will not be directly shared because: The study involves sensitive health information from people living with HIV, a vulnerable population. Participant informed consent does not include unrestricted public data sharing. Data are derived from multiple sources (CDC registries, hospital EMRs, insurance claims) with strict data use agreements that prohibit open distribution. Thus, IPD will not be shared as a public repository deposit. Access, if granted, would be controlled and require a signed data use agreement.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.
Of 165 non-industry observational studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 83. This study's planned 12 months is below that.
Counting every sponsor, half of 177 studies reached it within 44 months; a quarter within 19 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acquired Immunodeficiency Syndrome →
Southwest Medical University